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Glioblastoma (GBM) is a disease without any definite cure. Numerous approaches have been tested in efforts to conquer this brain 
disease, but patients invariably experience recurrence or develop resistance to treatment. New surgical tools, carefully chosen 
samples, and experimental methods are enabling discoveries at single-cell resolution. The present article reviews the cell-of-origin 
of isocitrate dehydrogenase (IDH)-wildtype GBM, beginning with the historical background for focusing on cellular origin and 
introducing the cancer genesis patterned on firework. The authors also review mutations associated with the senescence process 
in cells of the subventricular zone (SVZ), and biological validation of somatic mutations in a mouse SVZ model. Understanding GBM 
would facilitate research on the origin of other cancers and may catalyze the development of new management approaches or 
treatments against IDH-wildtype GBM.
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INTRODUCTION
Isocitrate dehydrogenase (IDH)-wildtype glioblastoma 
(GBM) is a disease with a dismal prognosis, a distinction that 
has led to GBM being dubbed the “emperor of all cancers”. 
The disease progression is rapid, and even with standard ther-
apy53) and supra-total resection52), the median survival of pa-
tients from diagnosis is approximately 14–20 months53,63).
There are continuing efforts by researchers in diverse disci-
plines, including epidemiology and molecular biology, to 
identify the cause of GBM. Epidemiological research on GBM 
suggests numerous risk factors that should be taken into ac-
count, such as irradiation of the head8,23,46,50,55) and the allergic 
history of patient4). Biological approaches for determining the 
cause of GBM include attempts to identify molecular signa-
tures in patient samples (e.g., DNA mutations)61), the use of in 
vivo mouse models58), and investigation of progenitor cells of 
GBM3,13,43).
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This article reviews the proof-of-concept that GBM origi-
nates in the subventricular zone (SVZ) from the microscale 
perspective such as a molecular biology with a cellular level 
resolution. The first sections present a brief overview of the 
disease and recapitulate the importance of mutations in the 
development of GBM. The remaining sections describe the 
cell-of-origin of GBM and the cancer genesis patterned on 
firework from SVZ43) and discuss a new hypothesis driving 
GBM research.
HISTORY : PROGRESS TOWARD THE STEM 
CELL ORIGIN OF GBM
There are plenty of discussions and arguments about the 
existence of the cell-of-origin from the early era of neuro-on-
cology whether the disease originates from embryonic cells or 
dedifferentiated cells51). The brain cancer model induced from 
the mutation of specific cells of brain is blurring the gap be-
tween those two sides2) by leading an edge of this field with a 
subsequent drug discovery targeting GBM58). 
The cell-of-origin of GBM has been suspected to have char-
acteristics of a stem cell, and this cell type has also been regard-
ed as the source of tumor recurrence22). There have been many 
trials conducted to isolate such treatment-resistant insidious 
cells from the tumor tissues3,34,41). Those cells were labeled as tu-
morspheres27,35,36) and their behaviors and characteristics have 
been validated from multiple sources14,25,30,39,42,49,64). As the pa-
tient-derived tumor cells are heterogeneous in the sample di-
mension (patient age, the size and location of the sample in the 
original tumor mass, sample control, purity of samples, or pre-
vious treatments), the mutation-induced tumor model has been 
accepted as another robust and predictable platform in the re-
peated experiments and clearly demonstrates the consequences 
of mutation1,20,43) better than the orthotopic xenograft by pri-
mary tumorsphere31,35,38,42).
An epiphany came from the experience of 5-aminolevulinic 
acid (5-ALA) fluorescence without any tumor cells in the tu-
mor specimen by pathologic examinations45). During surgery 
to remove GBM, high fluorescence of 5-ALA was found in the 
walls of ventricles45), which are non-coincidentally exposed af-
ter supra-total resection (or a so-called planned lobecto-
my)52,53). Moon et al.45) described interesting patterns of 5-ALA 
fluorescence in the ventricular wall of brain tumor patients. 
What they found the most interesting was the ventricular 
walls with positive 5-ALA fluorescence without magnetic res-
onance imaging enhancement and no tumor cells in the pa-
thology, a finding that perplexed surgeons45).
Concurrence of 5-ALA positive tissues with no tumor cells 
in the ventricle sample45) helped and guided us to find the ori-
gin of GBM in the in vivo model43). This 5-ALA glittering tu-
mor negative samples from the ventricular wall or the SVZ 
has a pattern of mutations that has not been previously dis-
covered. By comparing those mutation patterns, a novel way 
of understanding the disease could be revealed. The tumor-
private mutations in the tumor tissue might facilitate the de-
velopment of a new targeted therapy. In addition, the anatom-
ical location of those cells would mature the Big Bang 
theory7,60) into the Firework theory of subventricular abnormal 
cells43).
ETIOLOGY
Epidemiologic studies have linked a number of pollutants 
to the incidence of GBM48). Ionizing radiation to the head at a 
younger age increases the risk of glioma and meningio-
ma8,23,46,50,55). An allergic or atopic disease has been associated 
with a lower risk of GBM, and consistently with lower-grade 
glioma4). DNA mutations and its consequent syndromes in-
crease the risk of acquiring GBM32,48), such as Turcot syn-
drome (from mismatch repair-deficiency)15), Li-Fraumeni 
syndrome (from the germline mutation of TP53)37) and neu-
rofibromatosis type 1 (from NF1 gene)26,59).
However, there are additional unproven and controversial 
risk factors. One example is non-ionizing radiation from cel-
lular phones. Studies have not shown a consistent increase in 
the risk of glioma24). Another example is Radon exposure 
which reported to be associated with the risk of glioma in a 
Danish cohort9), but neither radon exposure nor background 
radiation was associated with glioma incidence in a cohort of 
British children28). Inconsistent results have been obtained 
with respect to the association of GBM development with ex-
posure to air pollutants or particulate matter, owing in part to 
difficulties in measuring exposure history5). There is hardly 
any or no evidence linking insecticides, rubber processing, 
pesticides, farming, solvents, metal fumes, or jet engine man-
ufacturing to the incidence of glioma48,54).
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IDENTIFICATION OF SOMATIC MUTATIONS IN 
SVZ STEM CELLS
Two senescence-associated mutational patterns were found 
in GBM : mutational signatures 1 and 543). These two types 
dominated the mutation profile of SVZ samples of the astro-
cytic ribbon (SVZ‡ in Fig. 1A, 33% [7.8 genes out of 23 total 
genes] and 45% [10.4 genes out of 23 total genes] for signature 
1 and 5 respectively in the SVZ samples)43).
The average number of genes for mutation signature 1 
jumped up from 7.8 genes (SVZ) to 81.9 genes in tumor sam-
ples of the Severance GBM cohort (10.5 fold increase)43). While 
the fold change of average number of genes that contribute to 
mutation signature 5 (fold 0.71, calculated from 10.4 genes of 
SVZ to 7.4 genes of the tumor) remains relatively stable as that 
of other signatures (fold 1.18, calculated from 4.8 genes of SVZ 
to 5.7 genes in the tumor)43). These findings suggest that GBM 
arises from the senescence process, especially if we focus on 
the number of genes of mutational signature 1 and 5 from 
SVZ to tumor, or alternatively from other causes that are as-
sociated with age.
DIRECTION OF CLONAL EVOLUTION
Accumulation of mutations in both the stem cells and the 
tumor region raises questions regarding the origin of the mu-
tations. Are mutations in both tumors and SVZ related? Are 
they coincidental? Do mutations in the SVZ reflect contami-
nation from the tumor? To deconvolute this complex pattern 
of mutations, the authors compared shared mutations (i.e., 
those in common to both the SVZ and tumor) and tumor-ex-
Fig. 1. Cell-of-origin of IDH-wildtype GBM and GBM genesis mechanism. A : Illustration of IDH-wildtype GBM genesis from the SVZ43). Left : gross 
structure of the tumor in the brain. Red arrow (yellow background in the arrowhead) indicates migrating GBM origin cell from SVZ (red line under the 
sky blue lateral ventricle) to the hemisphere. Red arrow with a pink background in the arrowhead indicates the explosion (or evolutionary increase in 
heterogeneity) of tumor cells that creates the tumor bulk. Right : schematic overview of tumorigenesis from the SVZ to the cortex (below → top). Some 
portion of cells in the astrocytic band in the SVZ (‡) acquire mutations (illustrated by asterisks with blue in the SVZ; additional mutations are depicted in 
cells of the GBM in green and red asterisks) as an incidental consequence of senescence (*), with mutations in the TERT promoter serving as the possible 
initial step (†), followed by mutations in TP53, PTEN and EGFR, among others. B : Illustration of the hypothetical SVZ origin of IDH-wildtype GBM 
recurrence via route 1 or 2. Route 1 indicates same site recurrence, while route 2 indicates different site recurrence from the GBM cell-of-origin in the 
SVZ. GBM : glioblastoma, IDH : isocitrate dehydrogenase, TERTp : promoter of telomerase reverse transcriptase (Gene symbol : TERT), p53 : tumor protein 
p53 (Gene symbol : TP53), EGFR : epidermal growth factor receptor, PTEN : phosphatase and tensin homolog, CSF : cerebrospinal fluid, SVZ : 
subventricular zone.
A
B
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clusive mutations (i.e., those not found in the SVZ)43). There 
were several shared mutations in the tumor-free SVZ and 
GBM bulk tumor, including those in the TERT promoter43). 
An analysis of variant allele frequencies (VAFs) and single-cell 
sequencing results revealed a unidirectional pattern from SVZ 
to bulk tumor. A two-dimensional VAF plot in a previous re-
port43) showed unique patterns of shared mutations between 
the tumor and the SVZ, with low-level driver mutations being 
located near the y-axis or tumor-axis. However, the tumor-
contaminated SVZ-tumor pair showed more genes that are 
spread along the identity line as opposed to the uncontami-
nated SVZ-tumor pair43) (Fig. 1A).
Single-cell sequencing of the DNA of bulk tumors also vali-
dated the result showing directionality from the SVZ to the 
tumor43). Twenty-four clones were derived from one IDH-
wildtype GBM patient (GBM245)43). The genes on the table of 
Lee et al.43) are subset of those genes of directionality. This 
surprising pattern of mutation was later confirmed from the 
intraventricular injection of plasmids to induce mutation in 
the SVZ16,43).
PROGRESSION OF MUTATIONS IN GBM FROM 
THE SVZ
Mutations oftentimes start with TERT promoter mutations 
in cells of the astrocytic ribbon in SVZ under the ventricle 
(TERTp† in Fig. 1A). With additional mutations in oncogenes, 
the mutated cells from SVZ migrate to the cortex and mani-
fest as the GBM (Fig. 1A, right)43). The authors searched for 
mutations in triple-matched samples of tumor-free SVZ, 
GBM tumor, and normal brain cortex (or blood)43). The au-
thors have hypothesized that the SVZ, which includes neural 
stem cells, is suspected of being the origin of tumors43); muta-
tions then progress from the SVZ to the tumor mass. In addi-
tion to this directionality, the number of mutations increases 
dramatically after the cell-of-origin reaches the cortex. As de-
scribed in the previous study of Lee et al.43), about 20 different 
somatic mutations of SVZ that contribute to the mutational 
patterns increased to around 100 mutations in the tumor. 
Furthermore, mutational signature 1 dominated most muta-
tions in tumors, whereas mutational signature 5 was preserved 
Fig. 2. Firework pattern of IDH-wildtype GBM genesis. A : Artistic illustration of IDH-wildtype GBM originating from the SVZ (colored in gold). Each 
firework trail corresponds to a different cancer clone. In this metaphorical depiction, the SVZ is represented as a cannon on the ground, denoting the 
starting point of GBM genesis. B : Conceptual illustration of the time line of the genesis of the firework pattern of IDH-wildtype GBM. Horizontal 
recurrence (or classical model) : GBM recurs from SVZ (red) → tumor (blue) → recurrence (green), vertical recurrence (hypothetical model) : primary GBM 
originates from SVZ (red) → tumor (blue), and it recurs from SVZ (red) → recurrent tumor (orange). GBM : glioblastoma, SVZ : subventricular zone, IDH : 
isocitrate dehydrogenase.
A B
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at about the same level between the SVZ and the tumor43). 
This pattern is slightly different version of the Big Bang con-
cept and, considering the anatomic location of the progres-
sion, the authors refer to it as a “Firework” pattern (Fig. 2).
BIOLOGICAL VALIDATION
Deep under the ependymal layer of the SVZ is a ribbon-like 
feature called the astrocytic ribbon57) (SVZ‡ in Fig. 1A). This 
area is populated by neural stem cells in both mouse and hu-
man brains65). Using molecular techniques described below, 
we introduced three types of mutations into the population of 
cells in the SVZ. These mutation-bearing cells migrated to the 
cortex, ultimately forming high-grade gliomas43) (Fig. 1A), 
presenting with firework-like GBM genesis (Fig. 2A).
A mass of GBM is created in the cortex by the mutation in 
the SVZ cells43). Crossbred mice (postnatal day 2–3 pups) car-
rying LSL-tdTomato and LSL-EGFRviii71) were used for these 
experiments43). A Cre-containing CRISPR/Cas9 plasmid was 
electroporated into one side of the ventricle in the brain to 
knock out Pten and Trp53 (mouse analog of human TP53) 
genes using single guide RNA (sgRNA) for these genes. After 
injection into the ventricular space with a sharp needle, the 
electroporation device was applied to deliver the plasmid into 
the SVZ43). In the presence of the mutations, brain tumors de-
veloped in 90% of mice (9/10), with 67% of tumors developing 
in a region distant from the mutation-arising SVZ, and these 
mice showed a median survival of around 20 weeks43).
Tumorigenesis, or Cancer genesis from the triple mutations 
marks the important step in the research of GBM61). By this 
finding43), more subtle nature of IDH-wildtype GBM can be 
revealed in the subsequent researches.
HYPOTHESIS : RECURRENCE OF GBM FROM 
THE SVZ 
One of the next steps in the research of IDH-wildtype GBM 
should be related with the recurrence pattern of GBM (The 
hypothesis on the recurrence of GBM). Careful selection of 
samples without tumor in the SVZ is the beginning point of 
this research. Recent article by Watts group61) is one example 
of selecting the tumor-invaded SVZ (median tumor content 
22.1%, rather than tumor-free SVZ) by the IDH-wildtype 
GBM and its results and implications should be carefully con-
templated in the research of vertical recurrence from the cell 
of SVZ (Fig. 2B). 
GBM recurs after irradiation of tumor margins at varying 
depth69). Although irradiating the SVZ appears to have a prog-
nostic benefit for GBM patients29,47), it does not cure these pa-
tients or prevent exacerbation of symptoms. There are at least 
two scenarios for recurrence of IDH-wildtype GBM. In the 
first case, GBM-initiating cells already present in the paren-
chyma of the brain restart the tumor after a dormant period 
(Fig. 2B, horizontal recurrence). In the second, dormant cells 
in the SVZ re-migrate to the tumor bed area, where they cre-
ate the recurrent tumor (Fig. 1B, the only hypothesis in this 
article; Fig. 2B, vertical recurrence). We hope to resolve the 
second phenomenon using tumor-free SVZ samples from 
GBM patients.
FUTURE : DEVELOPMENT OF THERAPEUTICS 
TARGETING THE SVZ
Many previous attempts to treat GBM have failed and the 
list harbors 5-f luorouracil and methotrexate10). A break-
through in treating GBM came with the application of alkyl-
ating agents18,62,67). Nitrosoureas proved the most effective at 
the time, and it became the most commonly used drugs for 
the management of brain tumors, including GBM56,70). Their 
antitumor effects were widely accepted and even led to the de-
velopment of an implantable chemotherapeutic system im-
pregnated with the nitrosourea derivative carmustine11).
However, these nitrosoureas had toxicity issues, and temo-
zolomide subsequently gained popularity because of its limit-
ed adverse effects compared with earlier alkylating agents6). 
But even temozolomide proved to be ineffective in treatment 
of recurrent GBM similarly to other alkylating agents33,44,66). 
And the therapeutic efficacy of other novel options is limited 
in Bevacizumab19,21,68), IDH-targeting drugs12) and immuno-
therapy17,40).
After the repeated efforts to treat the tumor itself, the origin 
of GBM emerged as the next generation target. Ultimately, in 
vitro and in vivo models will accelerate the screening for drugs 
that can preemptively target the initial process of cancer gene-
sis with firework pattern from SVZ.
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CONCLUSION
Mutated neural stem cells, that are present in the astrocytic 
ribbon in the SVZ, may migrate to the brain cortex and gen-
erate IDH-wildtype GBM with/or without any molecular or 
environmental cue43). While this concept has been demon-
strated scientifically, elucidating the detailed mechanism un-
derlying the GBM genesis process will require additional in-
vestigation. Our ongoing research efforts would focus on 
identifying the cell-of-origin to develop a potential treatment 
option for IDH–wildtype GBM, the “Emperor of cancer”. 
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